A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Fate Therapeutics
Tizona Therapeutics, Inc
Eli Lilly and Company
Fate Therapeutics
NKGen Biotech, Inc.
GOG Foundation
Eli Lilly and Company
Eli Lilly and Company